These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T, Pattison S, Golightly D, Idamakanti N, Pinkstaff A, Kaloss M, Barjot C, Chamberlain JS, Kaleko M, Connelly S. Mol Ther; 2002 Jan; 5(1):63-73. PubMed ID: 11786047 [Abstract] [Full Text] [Related]
5. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Kang Y, Xie L, Tran DT, Stein CS, Hickey M, Davidson BL, McCray PB. Blood; 2005 Sep 01; 106(5):1552-8. PubMed ID: 15886327 [Abstract] [Full Text] [Related]
8. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S. Mol Ther; 2001 Mar 01; 3(3):329-36. PubMed ID: 11273775 [Abstract] [Full Text] [Related]
9. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S. Blood; 2003 Mar 01; 101(5):1734-43. PubMed ID: 12406898 [Abstract] [Full Text] [Related]
13. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KM. Proc Natl Acad Sci U S A; 1999 Nov 09; 96(23):13324-9. PubMed ID: 10557319 [Abstract] [Full Text] [Related]
15. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD. Blood; 1996 Nov 15; 88(10):3846-53. PubMed ID: 8916949 [Abstract] [Full Text] [Related]
16. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. Brown BD, Shi CX, Rawle FE, Tinlin S, McKinven A, Hough C, Graham FL, Lillicrap D. J Thromb Haemost; 2004 Jan 15; 2(1):111-8. PubMed ID: 14717974 [Abstract] [Full Text] [Related]
18. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion. Bristol JA, Gallo-Penn A, Andrews J, Idamakanti N, Kaleko M, Connelly S. Hum Gene Ther; 2001 Sep 01; 12(13):1651-61. PubMed ID: 11535168 [Abstract] [Full Text] [Related]
19. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Chuah MK, VandenDriessche T, Morgan RA. Hum Gene Ther; 1995 Nov 01; 6(11):1363-77. PubMed ID: 8573610 [Abstract] [Full Text] [Related]
20. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Proc Natl Acad Sci U S A; 2005 Apr 26; 102(17):6080-5. PubMed ID: 15837921 [Abstract] [Full Text] [Related] Page: [Next] [New Search]